La Jolla Pharmaceutical (NASDAQ:LJPC) & Enzon Pharmaceuticals (NASDAQ:ENZN) Head-To-Head Review

La Jolla Pharmaceutical (NASDAQ:LJPC) and Enzon Pharmaceuticals (OTCMKTS:ENZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Volatility & Risk

La Jolla Pharmaceutical has a beta of 2.68, indicating that its stock price is 168% more volatile than the S&P 500. Comparatively, Enzon Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.

Insider & Institutional Ownership

69.7% of La Jolla Pharmaceutical shares are owned by institutional investors. Comparatively, 0.0% of Enzon Pharmaceuticals shares are owned by institutional investors. 29.5% of La Jolla Pharmaceutical shares are owned by insiders. Comparatively, 0.1% of Enzon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares La Jolla Pharmaceutical and Enzon Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
La Jolla Pharmaceutical $23.05 million 8.54 -$116.51 million ($4.30) -1.68
Enzon Pharmaceuticals $210,000.00 37.75 -$980,000.00 N/A N/A

Enzon Pharmaceuticals has lower revenue, but higher earnings than La Jolla Pharmaceutical.

Analyst Ratings

This is a breakdown of recent ratings for La Jolla Pharmaceutical and Enzon Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
La Jolla Pharmaceutical 0 2 1 0 2.33
Enzon Pharmaceuticals 0 0 0 0 N/A

La Jolla Pharmaceutical presently has a consensus price target of $19.50, suggesting a potential upside of 170.46%. Given La Jolla Pharmaceutical’s higher possible upside, research analysts plainly believe La Jolla Pharmaceutical is more favorable than Enzon Pharmaceuticals.

Profitability

This table compares La Jolla Pharmaceutical and Enzon Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
La Jolla Pharmaceutical -355.86% N/A -65.61%
Enzon Pharmaceuticals -326.92% -11.28% -9.14%

Summary

La Jolla Pharmaceutical beats Enzon Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply